CRS is the most common adverse event following CAR-T cell therapy and is caused by the release of large amounts of inflammatory factors (IL-6, IL-1, GM-CSF, etc.), which can lead to fever and, in severe cases, heart failure and death (120). Here, CSF2 is linked to congenital rubella syndrome.